Navigation Links
CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology

ORLANDO, Fla., Jan. 28 /PRNewswire/ -- CORD:USE Cord Blood Bank congratulates CORD:USE team member and highly esteemed advisor Hal Broxmeyer, Ph.D., on becoming the 2010 President of the American Society of Hematology ("ASH").

"Being elected as President of such an important organization as ASH is a tremendous achievement and a testament to the pioneering research and body of work that Dr. Broxmeyer has performed, and we are deeply honored to have him as an integral member of our team," said CORD:USE President and CEO Edward Guindi, M.D.  

The American Society of Hematology is the world's largest professional society, with more than 16,000 members from 97 countries, concerned with the causes and treatments of blood disorders.  The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Dr. Broxmeyer is internationally recognized as a founder of the field of umbilical cord blood stem cell transplantation.  He helped start the first cord blood banking company and was involved in planning and coordinating the first successful cord blood transplant performed in 1988.  He set up the first proof-of-principal cord blood bank, which supplied the first five cord blood collections for HLA-matched sibling cord blood transplants.  As a result of the research of Dr. Broxmeyer and his colleagues, cord blood has been used in transplantation therapy for more than 16,000 patients with over 70 life-threatening diseases, such as leukemia, lymphoma, thalassemia, and sickle cell anemia.  

Dr. Broxmeyer is the Chairman of the Department of Microbiology and Immunology, former Director of the Walther Oncology Center and Mary Margaret Walther Professor Emeritus, Distinguished Professor of the Indiana University School of Medicine.  He is a member of the Cord Blood Committee of the National Marrow Donor Program ("NMDP") and has been a member of the Health Resources and Services Administration's ("HRSA") Advisory Council on Blood Stem Cell Transplantation.  In his more than 30 year career, he has authored over 600 publications and has served as an editor on many peer reviewed journals.  Dr. Broxmeyer has won numerous awards, including the highly prestigious E. Donnall Thomas Prize from ASH.  

About CORD:USE Cord Blood Bank

CORD:USE Cord Blood Bank, headquartered in Orlando, Florida, is creating a large, ethnically diverse, high quality inventory of available cord blood stem cell units for the many patients in need of a potentially life-saving transplant.  CORD:USE has assembled a team of world leaders in the field of cord blood banking and transplantation.  CORD:USE has entered into agreements with hospitals across the country to provide mothers the option to donate their babies' cord blood.  CORD:USE makes these cord blood units available to transplanters throughout the country and around the world, as a critical component in their patients' treatment.  CORD:USE is accredited by the Foundation for the Accreditation of Cellular Therapy ("FACT") and lists all of its units on the National Marrow Donor Program's Registry.  CORD:USE has also been selected by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health as one of the high quality cord blood banks to build the federally supported National Cord Blood Inventory.  For more information, please visit




Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. BioMosaics Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
8. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
9. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
10. Microlifes Home Blood Pressure Monitors Proven Accurate Even for Critical Patients
11. WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests
Post Your Comments:
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):